Top 10 MS Australia news stories of 2024
14 January 2025
As we take our first steps into 2025, let’s take a moment to look back at ten of the biggest MS Australia news stories from 2024.
As we take our first steps into 2025, let’s take a moment to look back at ten of the biggest MS Australia news stories from 2024.
In a groundbreaking development, the PBAC has recommended listing ravulizumab (Ultomiris®) on the PBS for adults with NMOSD, marking a revolutionary step forward in NMOSD care.
The PBAC has recommended a proposed amendment to allow nurse practitioners to prescribe certain MS treatments under the PBS—a game-changer that will dramatically improve access to care, especially in regional and remote areas.
CEO Rohan Greenland outlines the key activities for 2025, which promises to be another big and productive year for MS Australia and the MS community. Tighten your seat belts!
Christmas is the season of giving, and for the last seven years, two young men from Canberra, James
MS Australia-supported researchers found autologous haematopoietic stem cell transplantation (AHSCT) has no advantages over natalizumab in treating progressive MS.
A new study has revealed that an MS risk gene changes how the immune system responds to EBV, linking these two major risk factors.
The Frontiers in MS Research Symposium showcased cutting-edge advancements in MS prevention, care, and management, fostering collaboration among experts, healthcare professionals, and the MS community to drive meaningful progress and innovation.
MS Australia is bringing together the nation’s top researchers to unlock the complex link between EBV) and MS; with the potential to revolutionise how we treat, prevent, and ultimately cure MS.Â